Bicara Therapeutics Inc. (BCAX) Form 8-K — Nov 9, 2026
Bicara Therapeutics reported a Q3 2026 net loss of $71.2 million ($1.04 per share), roughly double the $36.3 million loss a year earlier, driven by R&D spending that rose to $56.5 million on the FORTIFI-HN01 pivotal trial and G&A that climbed to $19.2 million ahead of potential commercialization. The company achieved substantial enrollment in the FORTIFI-HN01 pivotal trial of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck cancer, with topline results from an interim analysis expected in mid-2027. The FORTIFI-FLEX alternate dosing study is also enrolling, with data expected by the time of potential U.S. approval.
Key figures
- Revenue
- 0
- Guidance
- Existing cash, cash equivalents and marketable securities expected to fund operations into the first half of 2029
- Cash Position
- 442300000
- Ga expense q3
- 19235000
- Rd expense q3
- 56476000
- Interim analysis timing
- mid-2027
- Ga expense q3 prior year
- 7701000
- Rd expense q3 prior year
- 32975000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.